Management of Thyroid Nodule with Rising TSH in Patient on Semaglutide

Immediate Thyroid Nodule Management

The American College of Endocrinology and the National Comprehensive Cancer Network recommend fine-needle aspiration (FNA) of the thyroid nodule given the suspicious ultrasound features, elevated TSH, and nodule size, while simultaneously addressing the rising TSH with levothyroxine therapy and monitoring for semaglutide-thyroid medication interactions 1, 2, 3, 4
The nodule's hypoechoic appearance with peripheral vascularity are suspicious ultrasound features that warrant FNA regardless of size, according to the National Comprehensive Cancer Network guidelines 4
TSH measurement is part of the initial workup, and an elevated TSH significantly increases malignancy risk, as stated by the American Thyroid Association 1, 2, 3, 4
Patients with elevated TSH levels have increased risk of thyroid malignancy in nodular disease, with significant elevation in carcinoma risk when TSH exceeds 1.64 mU/L, based on evidence from the Journal of the National Comprehensive Cancer Network 2
The nodule size of 0.8 cm meets the threshold for FNA when combined with suspicious features, according to the American College of Radiology Thyroid Imaging, Reporting and Data System (TI-RADS) 1, 4

Perform ultrasound of the lateral neck to evaluate for lymphadenopathy, as cervical lymph node involvement is a high-risk feature, recommended by the National Comprehensive Cancer Network 1, 2, 4
FNA any clinically suspicious lymph nodes if identified, as suggested by the American Head and Neck Society 1, 2

Start levothyroxine supplementation given the TSH level, which represents symptomatic hypothyroidism, according to the Endocrine Society guidelines 5
For a patient without cardiac disease or multiple comorbidities, full replacement dosing can be estimated at approximately 1.6 mcg/kg/day using ideal body weight, based on recommendations from the American Association of Clinical Endocrinologists 5
Monitor TSH every 6-8 weeks while titrating levothyroxine to goal of TSH within the reference range, with particular vigilance given concurrent semaglutide therapy, as advised by the American Diabetes Association 5

If FNA shows benign cytology, continue levothyroxine therapy to normalize TSH, targeting TSH within the reference range, according to the American Thyroid Association guidelines 5, 3
If FNA shows malignancy or suspicious cytology, proceed to surgical evaluation for thyroidectomy based on NCCN guidelines, recommended by the National Comprehensive Cancer Network 1, 2
Post-operatively, TSH suppression therapy would be indicated, with target TSH <0.1 mU/L if high-risk features present, as stated by the American Thyroid Association 1, 2, 3

Do not delay FNA while addressing the TSH abnormality—these should be pursued simultaneously, as recommended by the National Comprehensive Cancer Network 1, 4
Do not assume the rising TSH is solely due to semaglutide; this represents true hypothyroidism requiring treatment, according to the Endocrine Society guidelines 5
Do not use TSH suppression therapy for benign nodules, as risks outweigh uncertain benefits, as stated by the American Thyroid Association 1, 2